Stephenson, a medical doctor with a particular interest in epidemiology and risk management, works closely with patients, academics/government, pharmacists, physicians and the industry to advance drug safety in the US.

Traditionally, drug safety groups have operated as drug safety factories, which incurred significant capital expenses in building infrastructure related to technology, processes, people and other operational investments.

The new China-US agreement on drug safety specifies new requirements for both countries for the registration and certification of drug ingredient manufacturers, as well as new procedures for information sharing, notification of adverse events, determination of counterfeits and facility access.

In response to a 2006 Institute of Medicine drug safety report and recommendations, the Food and Drug Administration in January outlined a "comprehensive commitment" to drug safety that includes strengthening science, improving communication and improving agency management.

Officials at the Food and Drug Administration are planning to reorganize its Center for Drug Evaluation and Research in an effort to improve the agency's approach to drug safety and to help improve drug development.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.